Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential effects of sleep deprivation on sleepwalking: Role of demographic and clinical profiles.

Sleep medicine·2024
Same author

The GBA p.Trp378Gly mutation is a probable French-Canadian founder mutation causing Gaucher disease and synucleinopathies.

Clinical genetics·2018
Same author

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Movement disorders : official journal of the Movement Disorder Society·2017
Same author

Parkinson's Disease Genetic Loci in Rapid Eye Movement Sleep Behavior Disorder.

Journal of molecular neuroscience : MN·2015
Same author

Cognitive impairment in obstructive sleep apnea.

Pathologie-biologie·2014
Same author

Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study.

Parkinsonism & related disorders·2013
Same journal

Cerebellum crus II cortical thickness as a cognitive brain reserve in Parkinson's disease.

Parkinsonism & related disorders·2026
Same journal

Serious games and virtual reality in Parkinson's disease rehabilitation: A systematic review of randomized controlled trials.

Parkinsonism & related disorders·2026
Same journal

Respiratory-swallow training in Parkinson's disease: Effects of a single session on swallowing safety and efficiency with exploratory comparisons of biofeedback.

Parkinsonism & related disorders·2026
Same journal

Levodopa responsive childhood-onset generalized dystonia with diaphragmatic involvement associated with an SPTBN2 variant.

Parkinsonism & related disorders·2026
Same journal

Approach to a case of Neuro-Gonadal disorder: Perrault syndrome.

Parkinsonism & related disorders·2026
Same journal

Parakinesia in Chorea: Why attribution of intention is misleading.

Parkinsonism & related disorders·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Predicting Parkinson's disease - why, when, and how?

R B Postuma1, J Montplaisir

  • 1Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada. ronald.postuma@mcgill.ca

Parkinsonism & Related Disorders
|January 20, 2010
PubMed
Summary
This summary is machine-generated.

Identifying early Parkinson's disease (PD) markers is crucial. Testing potential predictive markers in idiopathic REM sleep behavior disorder (RBD) offers a unique opportunity to diagnose preclinical PD.

Related Experiment Videos

Last Updated: Jun 17, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Area of Science:

  • Neurology
  • Neuroscience
  • Biomarker Research

Background:

  • Parkinson's disease (PD) has a preclinical stage where pathology begins before motor symptoms appear.
  • Current marker development focuses on early brainstem involvement and compensatory mechanisms.
  • Existing markers like decreased olfaction have limitations in lead time, predictive value, and specificity.

Purpose of the Study:

  • To explore and detail the results of testing potential predictive markers for Parkinson's disease.
  • To investigate the utility of idiopathic REM sleep behavior disorder (RBD) as a model for preclinical PD marker assessment.
  • To understand the implications of marker testing in idiopathic RBD for early PD diagnosis.

Main Methods:

  • Review of current principles in preclinical Parkinson's disease marker development.
  • Analysis of potential simple markers including olfactory, mood, autonomic, and sleep disturbances.
  • Evaluation of more invasive measures like autonomic testing, MIBG-scintigraphy, and functional imaging.
  • Focus on idiopathic RBD as a cohort for testing predictive markers due to its high conversion rate to PD or dementia.

Main Results:

  • Idiopathic RBD, characterized by loss of REM sleep atonia, presents a unique opportunity for preclinical disease prediction.
  • Approximately 50% of idiopathic RBD individuals develop PD or dementia within 10 years.
  • Marker testing in this cohort allows for direct assessment of predictive capabilities before clinical onset.

Conclusions:

  • Idiopathic RBD offers an unprecedented window to test and validate preclinical Parkinson's disease markers.
  • Successful marker identification in RBD could revolutionize early diagnosis and intervention strategies for PD.
  • Further research detailing marker testing results in idiopathic RBD is essential for advancing PD prediction.